Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

Status Completed

Clinical Trial Summary

Autism Spectrum Disorder (ASD) is a developmental disorder characterized by abnormalities in speech and communication, impaired social functioning and repetitive behaviors and restricted interests. Oxytocin (OT) is peptide that is known for its peripheral effects on facilitating uterine contractions and milk let-down; however, studies, mainly with rodents and non-human primates, has found that OT is involved in affiliative behaviors, including sexual behavior, mother-infant and adult-adult pair-bond formation, separation distress, and other aspects of social attachment. Moreover, OT is known to play an important role in repetitive behaviors and stress reactivity. Given that repetitive behaviors and deficits in social interaction are core symptom domains of autism, and that OT is involved in the regulation of repetitive and affiliative behaviors, it is believed that OT may play a role in the etiology of autism. Moreover, preliminary data obtained by Hollander and colleagues suggests that OT may be of value in treating core autism symptoms. Specifically, synthetic oxytocin administered via intravenous infusion to adults with autism spectrum disorders (ASD) produced significant reductions in repetitive behaviors and facilitated social cognition/memory in a double-blind, placebo-controlled cross-over laboratory challenge.

Encouraged by these findings, the primary aim of this study is to investigate the safety and therapeutic efficacy of intranasal OT in treating repetitive behaviors and social functioning/cognitive deficits in adults with ASD. This research embraces a translational approach to develop a novel treatment for core ASD symptoms; given that there are currently no Food and Drug Administration (FDA) approved medication treatments for core ASD symptoms, this research addresses an important unmet need in the field. The goal of this study is to evaluate the safety and efficacy of repeated Intranasal Oxytocin Treatment (INOT)administration in adults with ASD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01337687
Study type	Interventional
Source	Montefiore Medical Center
Contact
Status	Completed
Phase	N/A
Start date	October 2009
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02625116` - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting	`NCT06381856` - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Recruiting	`NCT02280746` - Gluten for Autism Spectrum Disorders	N/A
Completed	`NCT01945957` - Brain Imaging of Intranasal Oxytocin Treatment in Autism	Phase 1
Completed	`NCT01661855` - A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD	Phase 2
Completed	`NCT01780090` - Handheld Technology for Speech Development in Students With Autism	N/A
Completed	`NCT01691066` - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder	N/A
Completed	`NCT01592747` - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine	Phase 2
Completed	`NCT01694667` - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder	Phase 2
Active, not recruiting	`NCT01417026` - Intranasal Oxytocin and Learning in Autism	Phase 2
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Completed	`NCT01695200` - Omega-3 Fatty Acids in Autism Spectrum Disorders	Phase 4
Completed	`NCT02300597` - Internet-based Support for Young People With ADHD and Autism - a Controlled Study	N/A
Completed	`NCT01675414` - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)	N/A
Not yet recruiting	`NCT00695812` - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age	N/A
Recruiting	`NCT05910502` - Project AFECT (Autism Family Empowerment Coaching and Training Program)	N/A
Completed	`NCT02081027` - Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders	Early Phase 1
Completed	`NCT02797379` - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders	N/A
Terminated	`NCT01730079` - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed	`NCT01603225` - Transcranial Direct Current Stimulation and Autism

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders — INOT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms